Evidence map›Paper›PMID 41522655›Full record

ArticleInterventional cardiology (London, England)2025

All-comEr Registry of OCT (AERO) to Investigate the MLD-MAX Algorithm for OCT-guided-precision-PCI in Daily Routine: Rationale and Study Design of ILUMIEN-V-AERO.

Nitin Chandra Mohan, Mamas A Mamas, Mohammed Balgith, Tomaso Gori, Faisal Alqoofi, Mirvat Alasnag, Marcel Kunadt, Ziad A Ali, David M Leistner, Thomas W Johnson

Registry-linked trialAbstract read
In one paragraph

Article in Interventional cardiology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05324683 ("ILUMIEN-V - AERO"- All-comEr Registry of OCT), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05324683 active not recruitingnot on this map

"ILUMIEN-V - AERO"- All-comEr Registry of OCT (AERO) to Investigate the MLD-MAX Algorithm for OCT-guided-precision-PCI in Daily Routine

Typeobservational_patient_registrySponsorIHF GmbH - Institut für HerzinfarktforschungRan2023 to 2026Enrolled2,000ConditionsMyocardial IschemiaArmsNo intervention planned
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nitin Chandra MohanTranslational Health Sciences, Bristol Royal Infirmary, University of Bristol UK.
Mamas A MamasKeele Cardiovascular Research Group, Centre for Prognosis Research, Keele University Stoke-on-Trent, UK.ORCID https://orcid.org/0000-0001-9241-8890
Mohammed BalgithKing Abdulaziz Cardiac Center, King Abdulaziz Medical City Riyadh, Saudi Arabia.
Tomaso GoriDepartment of Cardiology, Cardiology I, University Medical Center Mainz Mainz, Germany.
Faisal AlqoofiInternal Medicine and Cardiology, Johns Hopkins Aramco Healthcare Dhahran, Saudi Arabia.
Mirvat AlasnagCardiac Center, King Fahd Armed Forces Hospital Jeddah, Saudi Arabia.ORCID https://orcid.org/0000-0002-8714-0334
Marcel KunadtIHF GmbH, Ludwigshafen am Rhein Germany.
Ziad A AliSt Francis Hospital and Heart Center Roslyn, NY, US.ORCID https://orcid.org/0000-0002-2482-3197
David M LeistnerDZHK (German Centre for Cardiovascular Research), Partner Site Rhein/Main Frankfurt, Germany.ORCID https://orcid.org/0000-0002-4351-420X
Thomas W JohnsonTranslational Health Sciences, Bristol Royal Infirmary, University of Bristol UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite class 1 recommendations and clinical evidence supporting optical coherence tomography (OCT), its adoption is limited. While randomised controlled trials show clinical benefits of OCT under strict protocols, its real-world performance is unclear. Aims and methods: All-comEr Registry of OCT (AERO) to Investigate the MLD-MAX Algorithm for OCT-guided-precision-PCI in Daily Routine (ILUMIEN-V-AERO; NCT05324683) is a prospective, multicentre OCT registry aiming to recruit 2,000 patients across sites in the UK, Germany and Saudi Arabia. The study seeks to evaluate the real-world use of an algorithmic approach to OCT-guided percutaneous coronary intervention (PCI) (MLD-MAX) and directly compares its outcomes to those from the ILUMIEN-IV randomised controlled trial. The primary endpoint for this comparison is post-PCI minimum stent area relative to the reference segments. Secondary endpoints include OCT imaging assessments (minimum stent area, edge dissection, stent malapposition, mean stent expansion, plaque protrusion, reference segment disease), procedural outcomes (procedural and fluoroscopy time, contrast use, renal replacement therapy) and clinical endpoints (a composite endpoint of target lesion failure [cardiac death, ischaemia-driven target lesion revascularisation, target vessel MI] and unplanned hospitalisation for unstable angina). All patients will undergo clinical follow-up at 30 days and 6 months to assess target lesion failure. Beyond the inclusion criteria of the ILUMIEN-IV trial, this study will explore the role of OCT in diagnosing acute coronary syndrome, its application in guiding drug-coated balloon PCI and the impact of core laboratory support and critical evaluation on operator performance. Conclusion: ILUMIEN-V-AERO is a large, prospective registry designed to assess the real-world performance of OCT and provide insights into its role in underexplored areas of PCI guidance.

Indexed as

core laboratoryIntracoronary imagingoptical coherence tomographypercutaneous coronary interventionstudy design

Identifiers

PMID41522655
PMCPMC12784262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.